Hudson Bay Capital Management
AXSM icon

Hudson Bay Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Hudson Bay Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.57M Buy
+15,220
New +$2.63M 0.01% 699
2025
Q3 		– Sell
-25,037
Closed -$2.61M – 1256
2025
Q2 		$2.61M Buy
+25,037
New +$2.65M 0.01% 726
2025
Q1 		– Sell
-12,500
Closed -$1.06M – 1305
2024
Q4 		$1.06M Buy
+12,500
New +$1.15M ﹤0.01% 737

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's AXSM Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 15,220 shares worth $2.57M. The stake represents 0.01% of the portfolio and ranks #699 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in AXSM as recently as Q2 2025.

Hudson Bay Capital Management first reported a position in AXSM in Q4 2024 and has held it in 3 quarters since. The position peaked at $2.61M in Q2 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Hudson Bay Capital Management held 15,220 shares of Axsome Therapeutics worth $2.57M as of Q1 2026.
  • Axsome Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Axsome Therapeutics made up 0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #699 holding.
  • Hudson Bay Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Axsome Therapeutics position peaked at $2.61M in Q2 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.